Comparative evaluation of radiolabeled bombesin analogs [177Lu]Lu-AMBA and [177Lu]Lu-RM2 for targeting GRPR in glioblastoma model
This study established targeting GRPR with both agonist and antagonist radioligands in glioma U-251 in vitro and in vivo models and recommends further development of antagonizing radiolabeled bombesin analog RM2, which showed in vivo superiority in tumor uptake and tumor-to-normal organ ratios (TNRs) over agonist AMBA radioligand.
Authors
- Michal Grzmil (ORCID: https://orcid.org/0000-0002-7866-8145)
- Roger Schibli (ORCID: https://orcid.org/0000-0002-1537-3833)
- Martin Spahn (ORCID: https://orcid.org/0000-0002-5770-9489)
- Martin Béhé (ORCID: https://orcid.org/0000-0002-1110-2665)
- Philipp Berger (ORCID: https://orcid.org/0000-0002-8147-1749)
Institutions
- Paul Scherrer Institute (CH)
- ETH Zurich (CH)
Publication Details
- Journal
- Nuclear Medicine and Biology
- Published
- 2025-06-06
- DOI
- https://doi.org/10.1016/j.nucmedbio.2025.109041
- Citations
- 2
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 2.72
Funders
- Physicians' Services Incorporated Foundation